Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 193Neoplasm Metastasis 22Prostatic Neoplasms, Castration-Resistant 20Breast Neoplasms 19Neoplasms 17Metastatic Castration Resistant Prostate Cancer 10Prostate Cancer Metastatic 7Metastatic Castration-Resistant Prostate Cancer 7Triple Negative Breast Neoplasms 6Metastatic Castration-resistant Prostate Cancer 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Pancreatic Neoplasms 5Castration-resistant Prostate Cancer 5Carcinoma, Non-Small-Cell Lung 5Melanoma 4Colorectal Neoplasms 4Bulbo-Spinal Atrophy, X-Linked 4Adenocarcinoma 4Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Prostate Adenocarcinoma 3Ovarian Neoplasms 3Carcinoma, Hepatocellular 3mCRPC 2Uterine Cervical Neoplasms 2Recurrence 2Prostatic Diseases 2Non-metastatic Castration-resistant Prostate Cancer 2Metastatic Hormone-sensitive Prostate Cancer 2

Interventions

pembrolizumab 1pamiparib 1famitinib 1enzalutamide 1apalutamide 1abiraterone 1Prednisone 1Prednisolone 1Poly(ADP-ribose) Polymerase Inhibitors 1Neoadjuvant Therapy 1Folfox protocol 1Fluorouracil 1Drug Therapy 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoadjuvant Therapy × enzalutamide × Clear all
NCT05406999 2022-08-16

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Recruiting
900 enrolled
Genitourinary

Neoadjuvant Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡